Top

Published in:

01-06-2014 | Original article

Complete pathological responses in locally advanced rectal cancer after preoperative IMRT and integrated-boost chemoradiation

Authors: Ovidio Hernando-Requejo, MD, Mercedes López, MD, Antonio Cubillo, MD, Almudena Rodriguez, MD, Raquel Ciervide, PhD, Jeannette Valero, PhD, Emilio Sánchez, MD, Mariola Garcia-Aranda, MD, Jesus Rodriguez, MD, Guillermo Potdevin, MD, Carmen Rubio, PhD

Published in: Strahlentherapie und Onkologie | Issue 6/2014

Abstract

Background and purpose

To analyze the efficacy and safety of a new preoperative intensity-modulated radiotherapy (IMRT) and integrated-boost chemoradiation scheme.

Patients and methods

In all, 74 patients were treated with IMRT and concurrent standard dose capecitabine. The dose of the planning target volume (PTV) encompassing the tumor, mesorectum, and pelvic lymph nodes was 46 Gy in 23 fractions; the boost PTV, at a dose of 57.5 Gy in 23 fractions, included the macroscopic primary tumor and pathological lymph nodes. The patients underwent surgery 6–8 weeks after chemoradiation.

Results

The complete treatment data of 72 patients were analyzed. Tumor downstaging was achieved in 55 patients (76.38 %) and node downstaging in 34 (47.2 %). In 22 patients (30.6 %), there was complete pathological response (ypCR). The circumferential resection margin was free of tumor in 70 patients (97.2 %). The 3-year estimated overall survival and disease-free survival rates were 95.4 and 85.9 % respectively, and no local relapse was found; however, ten patients (13.8 %) developed distant metastases. High pathologic tumor (pT) downstaging was shown as a favorable prognostic factor for disease-free survival. No grade 4 acute radiotherapy-related toxicity was found.

Conclusions

The IMRT and integrated-boost chemoradiation scheme offered higher rates of ypCR and pT downstaging, without a significant increase in toxicity. The circumferential margins were free of tumors in the majority of patients. Primary tumor regression was associated with better disease-free survival.

Nelson H, Petrelli N, Carlin A et al (2001) Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 93:583–596PubMedCrossRef

Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96PubMedCrossRef

Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740PubMedCrossRef

Rödel C, Martus P, Papadopoulos T et al (2005) Prognostic significance of tumor regresión after preoperative chemoradiotherapy for rectal cáncer. J ClinOncol 23:8688–8696CrossRef

Kim TH, Chang HJ, Kim DY et al (2010) Pathological nodal classification is the most discriminating prognostic factor for disease-free survival in rectal cáncer patients treated with preoperative chemoradiotherapy and curative resection. Int J Radiat Oncol Biol Phys 77:1158–1165PubMedCrossRef

Lee JH, Kim SH, Kim JG et al (2011) Preoperative chemoradiotherapy (CRT) followed by laparoscopic surgery for rectal cancer: predictors of the tumor response and the long-term oncologic outcomes. Int J Radiat Oncol Biol Phys 82:431e438

Bosset JF, Collette L, Calais G et al (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Eng J Med 355:1114–1123CrossRef

Bosset JF, Magnin V, Maingon P et al (2000) Preoperative radiochemotherapy in rectal cancer: long-term results of a Phase II trial. Int J Rad Oncol Biol Phys 46:323–327CrossRef

Rödel C, Grabenbauer GG, Papadopoulos T et al (2003) Phase I-II trial of capecitabine, oxaliplatin and radiation for rectal cancer. J Clin Oncol 21:3098–3104PubMedCrossRef

10.

Machiels JP, Duck L, Honhon B et al (2005) Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer. The RadiOxCape study. Ann Oncol 16:1898–1905PubMedCrossRef

11.

Hospers GA, Punt CJ, Tesselaar ME et al (2007) Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Duch Colorectal Cancer Group. Ann SurgOncol 14:2773–2779

12.

Gerard JP, Azria D, Gourgou-Bourgade S et al (2010) Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer. Results of the Phase III trial ACCORD 12/0405-Prodige 2. J ClinOncol 28:1638–1644CrossRef

13.

Winkler J, Zipp L, Knoblich J et al (2012) Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer. Strahlentherapie und Onkologie 188:377–382PubMedCrossRef

14.

Rödel C, Liersch T, Hermann RM et al (2007) Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J ClinOncol 25 110–117CrossRef

15.

Aschele CP, Cordio S, Rosati G et al (2009) Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial. J Clin Oncol 27(suppl): 170s, abstr CRA4008

16.

Fu KK, Pajak TF, Trotti A et al (2000) A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7–16PubMedCrossRef

17.

Kim DY, Kim TH, Jung KH et al (2006) Preoperative chemoradiotherapy with concomitant small field boost irradiation for locally advanced rectal cancer: a multi-institutional phase II study (KROG 04-01). Dis Colon Rectum 49:1684–1691PubMedCrossRef

18.

Jong Hoon Lee, Dae Yong Kim, Taek-Keun Nam et al (2012) Long-term follow-up of preoperative pelvic radiation therapy and concomitant boost irradiation in locally advanced rectal cancer patients: a multi-institutional phase II study (KROG 04-01) Int J Radiat Oncol Biol Phys 84:955–961CrossRef

19.

Cubillo A, Hernando-Requejo O, Garcia-Garcia E et al (2014) A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer. AM J Clin Oncol 37:117–121

20.

Freedman GM, Meropol NJ, Sigurdson ER et al (2007) Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 67:1389–1393PubMedCrossRef

21.

Jin-luan Li, Jia-fu Ji, Xiao-fan Li et al (2012) Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase II trial. Radiother Oncol 102:4–9CrossRef

22.

Chua YJ, Barbachano Y, Cunningham D et al (2010) Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRIdefined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 11:241–248PubMedCrossRef

23.

Ballonoff A, Kavanagh B, McCarter M et al (2008) Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial. Am J Clin Oncol 31:264–270PubMedCrossRef

24.

De Paoli A, Chiara, Luppi G et al (2006) Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: multicentric phase II study. Ann Oncol 17:246–251PubMedCrossRef

25.

Debucquoy A, Roels S, Goethals L et al (2009) Double blind randomized phase II study with radiation + 5-fluorouracil ± celecoxib for resectable rectal cancer. Radiother Oncol 93:273–278PubMedCrossRef

26.

Francois Y, Nemoz CJ, Baulieux J et al (1999) Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 17:2396PubMed

27.

Pettersson D, Cedermark B, Holm T et al (2010) Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg 97:580–587PubMedCrossRef

28.

Glynne-Jonnes R, Mawdsley S et al (2006) Alternative clinical endpoints in rectal cancer- are we getting closer? Ann Oncol 17:1239–1248CrossRef

29.

Dekker JW, Peeters KC, Putter H et al (2010) Metastatic lymph node ratio in stage III rectal cancer: prognostic significance in addition to the 7th edition of the TNM classification. Eur J Surg Oncol 36:1180–1186CrossRef

30.

Medical research Council Rectal Cancer Working Party (1996) Randomised trial of surgery versus radiotherapy followed by surgery for potentially operable advanced rectal cáncer. Lancet 348:1605–1610CrossRef

31.

Mawdsley S, Glynne-Jones R, Grainger J et al (2005) Can the histopathological assessment of the circumferential margin following pre-operative pelvic chemo-radiotherapy for T3/4 rectal cancer predict for three year disease free survival? Int J Radiation Oncol Biol Phys 63:745–752CrossRef

32.

Sautter-Bihl ML, Hohenberger W, Fietkau R et al (2013) Rectal cancer. Strahlentherapie und Onkologie 189:105–110PubMedCrossRef

Title: Complete pathological responses in locally advanced rectal cancer after preoperative IMRT and integrated-boost chemoradiation
Authors: Ovidio Hernando-Requejo, MD
Mercedes López, MD
Antonio Cubillo, MD
Almudena Rodriguez, MD
Raquel Ciervide, PhD
Jeannette Valero, PhD
Emilio Sánchez, MD
Mariola Garcia-Aranda, MD
Jesus Rodriguez, MD
Guillermo Potdevin, MD
Carmen Rubio, PhD
Publication date: 01-06-2014
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 6/2014
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-014-0650-0

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Complete pathological responses in locally advanced rectal cancer after preoperative IMRT and integrated-boost chemoradiation

Abstract

Background and purpose

Patients and methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background and purpose

Patients and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2014

Erratum to: The Erlangen Dose Optimization trial for low-dose radiotherapy of benign painful elbow syndrome

Influence of experience and qualification on PET-based target volume delineation

Evaluation of time, attendance of medical staff and resources for radiotherapy in pediatric and adolescent patients

Robotic radiosurgery as an alternative to brachytherapy for cervical cancer patients

Ist eine D2- gegenüber einer D1-Lymphknotendissektion für Patienten mit Magenkarzinom von Vorteil?

Is radiation an effective therapy in echinococcus multilocularis?